相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis
Yemil Atisha-Fregoso et al.
ARTHRITIS & RHEUMATOLOGY (2021)
B cell depletion therapies in autoimmune disease: advances and mechanistic insights
Dennis S. W. Lee et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
A Double-Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects
Azra Hussaini et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)
A review and meta-analysis of anti-ribosomal P autoantibodies in systemic lupus erythematosus
May Y. Choi et al.
AUTOIMMUNITY REVIEWS (2020)
Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience
A. Segarra et al.
LUPUS (2020)
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Eric F. Morand et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis
Antonis Fanouriakis et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Evidence for a pathogenic role of extrafollicular, IL-10-producing CCR6+B helper T cells in systemic lupus erythematosus
F. Facciotti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus
Lennard Ostendorf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Richard Furie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Phoenix from the flames: Rediscovering the role of the CD40-CD40L pathway in systemic lupus erythematosus and lupus nephritis
Meera Ramanujam et al.
AUTOIMMUNITY REVIEWS (2020)
DISCRIMINATION OF SYSTEMIC LUPUS (SLE) PATIENTS WITH CLINICAL RESPONSE TO OBEXELIMAB (XMAB®5871) BASED ON A PATTERN OF IMMUNOLOGIC MARKERS
J. T. Merrill et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
B cell memory: building two walls of protection against pathogens
Munir Akkaya et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Extrafollicular responses in humans and SLE
Scott A. Jenks et al.
IMMUNOLOGICAL REVIEWS (2019)
Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus
Rita Kansal et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity
Nikolaos I. Panousis et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
The Complex Association of FcγRIIb With Autoimmune Susceptibility
J. Sjef Verbeek et al.
FRONTIERS IN IMMUNOLOGY (2019)
Loss of an IgG plasma cell checkpoint in patients with lupus
Jolien Suurmond et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Patterns of ANA+ B cells for SLE patient stratification
Jolien Suurmond et al.
JCI INSIGHT (2019)
ALW peptide ameliorates lupus nephritis in MRL/lpr mice
Huixia Wang et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1) a randomised, controlled, phase 3 trial
Richard A. Furie et al.
LANCET RHEUMATOLOGY (2019)
A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea
Fengchun Zhang et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus
Tomonori Ishii et al.
MODERN RHEUMATOLOGY (2018)
Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab
Sherry Masoud et al.
RHEUMATOLOGY (2018)
Mechanisms of Tissue Injury in Lupus Nephritis
Giovanna Flores-Mendoza et al.
TRENDS IN MOLECULAR MEDICINE (2018)
IL-21 drives expansion and plasma cell differentiation of autoreactive CD11chiT-bet+ B cells in SLE
Shu Wang et al.
NATURE COMMUNICATIONS (2018)
Lupus-An Unrecognized Leading Cause of Death in Young Females: A Population-Based Study Using Nationwide Death Certificates, 2000-2015
Eric Y. Yen et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study
Joan T. Merrill et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Plasma Cell Differentiation Pathways in Systemic Lupus erythematosus
Susan Malkiel et al.
FRONTIERS IN IMMUNOLOGY (2018)
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial
Joan T. Merrill et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis
Liliana Michelle Gomez Mendez et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus
Scott A. Jenks et al.
IMMUNITY (2018)
Mouse models of lupus: what they tell us and what they don't
Mara Lennard Richard et al.
LUPUS SCIENCE & MEDICINE (2018)
Outcomes of rituximab therapy in refractory lupus: A meta-analysis
Fatma Alshaiki et al.
EUROPEAN JOURNAL OF RHEUMATOLOGY (2018)
Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus
Jeffrey M. Riggs et al.
LUPUS SCIENCE & MEDICINE (2018)
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial
Daniel J. Wallace et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Disruption of Pathogenic Cellular Networks by IL-21 Blockade Leads to Disease Amelioration in Murine Lupus
Jin-Young Choi et al.
JOURNAL OF IMMUNOLOGY (2017)
Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples
Venkat Reddy et al.
RHEUMATOLOGY (2017)
Plasma cell survival in the absence of B cell memory
Erika Hammarlund et al.
NATURE COMMUNICATIONS (2017)
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials
Megan E. B. Clowse et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016
Maria G. Tektonidou et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
An update on lupus animal models
Wei Li et al.
CURRENT OPINION IN RHEUMATOLOGY (2017)
Socioeconomic consequences of systemic lupus erythematosus
Megan R. W. Barber et al.
CURRENT OPINION IN RHEUMATOLOGY (2017)
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
J. T. Merrill et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE)
Kenneth C. Kalunian et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
D. A. Isenberg et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Age-associated B cells: key mediators of both protective and autoreactive humoral responses
Martin S. Naradikian et al.
IMMUNOLOGICAL REVIEWS (2016)
Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
Munther Khamashta et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
C1q and HMGB1 reciprocally regulate human macrophage polarization
Myoungsun Son et al.
BLOOD (2016)
Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients
Romain Banchereau et al.
CELL (2016)
DNA-reactive B cells in lupus
Jolien Suurmond et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
The genetic basis of systemic lupus erythematosus: What are the risk factors and what have we learned
Maria Teruel et al.
JOURNAL OF AUTOIMMUNITY (2016)
The BAFFling effects of rituximab in lupus: danger ahead?
Michael R. Ehrenstein et al.
NATURE REVIEWS RHEUMATOLOGY (2016)
The global burden of SLE: prevalence, health disparities and socioeconomic impact
Erin E. Carter et al.
NATURE REVIEWS RHEUMATOLOGY (2016)
Checkpoints for Autoreactive B Cells in the Peripheral Blood of Lupus Patients Assessed by Flow Cytometry
Susan Malkiel et al.
ARTHRITIS & RHEUMATOLOGY (2016)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis
Brad H. Rovin et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Ofatumumab treatment in lupus nephritis patients
Malena Loberg Haarhaus et al.
CLINICAL KIDNEY JOURNAL (2016)
Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers
William A. Figgett et al.
JOURNAL OF AUTOIMMUNITY (2015)
Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity
Jolien Suurmond et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus
Christopher M. Tipton et al.
NATURE IMMUNOLOGY (2015)
Longer duration of B cell depletion is associated with better outcome
Sofia Sapeta Dias et al.
RHEUMATOLOGY (2015)
Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus
Till Fassbinder et al.
ARTHRITIS RESEARCH & THERAPY (2015)
Animal models of interferon signature positive lupus
Haoyang Zhuang et al.
FRONTIERS IN IMMUNOLOGY (2015)
A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study
R. A. Furie et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)
David Isenberg et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
Daniel J. Wallace et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Impaired Suppressive Capacity of Activation-Induced Regulatory B Cells in Systemic Lupus Erythematosus
Nele Gao et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Cytokine-meciated regulation of plasma cell generation: IL-21 takes center stage
Leen Moens et al.
FRONTIERS IN IMMUNOLOGY (2014)
Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus
Yuko Shirota et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Suppression of Glomerulonephritis in Lupus-Prone NZB x NZW Mice by RN486, a Selective Inhibitor of Bruton's Tyrosine Kinase
Paola Mina-Osorio et al.
ARTHRITIS AND RHEUMATISM (2013)
Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-Blind, Phase III Study
Eduardo F. Mysler et al.
ARTHRITIS AND RHEUMATISM (2013)
MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies
Nicolas Molnarfi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis
Andrew L. Rankin et al.
JOURNAL OF IMMUNOLOGY (2013)
Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis
B. Duxbury et al.
LUPUS (2013)
Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up
Daniel J. Wallace et al.
RHEUMATOLOGY (2013)
Long-Lasting T Cell-Independent IgG Responses Require MyD88-Mediated Pathways and Are Maintained by High Levels of Virus Persistence
Forum M. Raval et al.
MBIO (2013)
Natural antibody to apoptotic cell membranes inhibits the proinflammatory properties of lupus autoantibody immune complexes
Jaya Vas et al.
ARTHRITIS AND RHEUMATISM (2012)
Efficacy and Safety of Rituximab in Patients With Active Proliferative Lupus Nephritis The Lupus Nephritis Assessment With Rituximab Study
Brad H. Rovin et al.
ARTHRITIS AND RHEUMATISM (2012)
Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells
H. Travis Ichikawa et al.
ARTHRITIS AND RHEUMATISM (2012)
Expression of Natural Autoantibodies in MRL-lpr Mice Protects from Lupus Nephritis and Improves Survival
Kaiissar Mannoor et al.
JOURNAL OF IMMUNOLOGY (2012)
Anti-IFN-α/β Receptor Antibody Treatment Ameliorates Disease in Lupus-Predisposed Mice
Roberto Baccala et al.
JOURNAL OF IMMUNOLOGY (2012)
B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen
Irene Puga et al.
NATURE IMMUNOLOGY (2012)
American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis
Bevra H. Hahn et al.
ARTHRITIS CARE & RESEARCH (2012)
Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus
Jack Hutcheson et al.
ARTHRITIS RESEARCH & THERAPY (2012)
Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial
Ellen M. Ginzler et al.
ARTHRITIS RESEARCH & THERAPY (2012)
BCR-signalling synergizes with TLR-signalling for induction of AID and immunoglobulin class-switching through the non-canonical NF-κB pathway
Egest J. Pone et al.
NATURE COMMUNICATIONS (2012)
B Cell Biomarkers of Rituximab Responses in Systemic Lupus Erythematosus
Edward M. Vital et al.
ARTHRITIS AND RHEUMATISM (2011)
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie et al.
ARTHRITIS AND RHEUMATISM (2011)
Increased Expression of B Cell Activation Factor Supports the Abnormal Expansion of Transitional B Cells in Systemic Lupus Erythematosus
Carolina Landolt-Marticorena et al.
JOURNAL OF RHEUMATOLOGY (2011)
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra et al.
LANCET (2011)
Netting Neutrophils Are Major Inducers of Type I IFN Production in Pediatric Systemic Lupus Erythematosus
Gina S. Garcia-Romo et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Recombination centres and the orchestration of V(D)J recombination
David G. Schatz et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Prolonged Effects of Short-Term Anti-CD20 B Cell Depletion Therapy in Murine Systemic Lupus Erythematosus
Kai W. Bekar et al.
ARTHRITIS AND RHEUMATISM (2010)
Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial
Joan T. Merrill et al.
ARTHRITIS AND RHEUMATISM (2010)
Anti-CD40L Immune Complexes Potently Activate Platelets In Vitro and Cause Thrombosis in FCGR2A Transgenic Mice
Liza Robles-Carrillo et al.
JOURNAL OF IMMUNOLOGY (2010)
The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88
Bing He et al.
NATURE IMMUNOLOGY (2010)
Regulatory B cells in autoimmunity: developments and controversies
Claudia Mauri et al.
NATURE REVIEWS RHEUMATOLOGY (2010)
Enhanced Selection of High Affinity DNA-Reactive B Cells Following Cyclophosphamide Treatment in Mice
Daisuke Kawabata et al.
PLOS ONE (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Role of Marginal Zone B Lymphocytes in Invariant NKT Cell Activation
Emilie Bialecki et al.
JOURNAL OF IMMUNOLOGY (2009)
Identification and Characterization of a Human CD5+ Pre-Naive B Cell Population
Jisoo Lee et al.
JOURNAL OF IMMUNOLOGY (2009)
Deficiency of Type I IFN Receptor in Lupus-Prone New Zealand Mixed 2328 Mice Decreases Dendritic Cell Numbers and Activation and Protects from Disease
Hemant Agrawal et al.
JOURNAL OF IMMUNOLOGY (2009)
EBI2 mediates B cell segregation between the outer and centre follicle
Joao P. Pereira et al.
NATURE (2009)
Dysregulation of germinal centres in autoimmune disease
Carola G. Vinuesa et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Abetimus sodium for renal flare in systemic lupus erythematosus
Mario H. Cardiel et al.
ARTHRITIS AND RHEUMATISM (2008)
The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-Containing antigens
Akanksha Chaturvedi et al.
IMMUNITY (2008)
Serum and Cerebrospinal Fluid Autoantibodies in Patients with Neuropsychiatric Lupus Erythematosus. Implications for Diagnosis and Pathogenesis
Hilda Fragoso-Loyo et al.
PLOS ONE (2008)
Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus
S. Nakano et al.
RHEUMATOLOGY (2008)
Follicular shuttling of marginal zone B cells facilitates antigen transport
Guy Cinamon et al.
NATURE IMMUNOLOGY (2008)
Treatment of lupus-prone of TLR7 and TLR9 leads to mice with a dual inhibitor reduction of autoantibody production and amelioration of disease symptoms
Franck J. Barrat et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2007)
Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA
Di Yu et al.
NATURE (2007)
Depletion of B cells in murine lupus: Efficacy and resistance
Anupama Ahuja et al.
JOURNAL OF IMMUNOLOGY (2007)
BAFF and MyD88 signals promote a lupuslike disease independent of T cells
Joanna R. Groom et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Essential autocrine regulation by IL-21 in the generation of inflammatory T cells
Roza Nurieva et al.
NATURE (2007)
Novel suppressive function of transitional 2 B cells in experimental arthritis
Jamie G. Evans et al.
JOURNAL OF IMMUNOLOGY (2007)
TLR agonists selectively promote terminal plasma cell differentiation of B cell subsets specialized in thymus-independent responses
Laurent Genestier et al.
JOURNAL OF IMMUNOLOGY (2007)
Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus
Rahul D. Pawar et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Generation of peripheral B cells occurs via two spatially and temporally distinct pathways
Robert Coleman Lindsley et al.
BLOOD (2007)
Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy
Jennifer H. Anolik et al.
ARTHRITIS AND RHEUMATISM (2007)
Systemic lupus erythematosus: all roads lead to type I interferons
Virginia Pascual et al.
CURRENT OPINION IN IMMUNOLOGY (2006)
Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus - Implications for the induction and maintenance of the autoimmune process
Eva D. Papadimitraki et al.
ARTHRITIS AND RHEUMATISM (2006)
Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus
Bailin Liang et al.
IMMUNOLOGY (2006)
Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF
Chaim O. Jacob et al.
JOURNAL OF IMMUNOLOGY (2006)
Nephritogenic anti-DNA antibodies regulate gene expression in MRL/lpr mouse glomerular mesangial cells
Xiaoping Qing et al.
ARTHRITIS AND RHEUMATISM (2006)
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Esther A. Obeng et al.
BLOOD (2006)
Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: Pharmacokinetic, pharmacodynamic, and toxicologic effects
Wendy G. Halpern et al.
TOXICOLOGICAL SCIENCES (2006)
Selection of anti-double-stranded DNA B cells in autoimmune MRL-lpr/lpr mice
Ching Chen et al.
JOURNAL OF IMMUNOLOGY (2006)
Similarities and differences between selective and nonselective BAFF blockade in murine SLE
M Ramanujam et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays
QL Zhen et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Decreased Lyn expression and translocation to lipid raft signaling domains in B lymphocytes from patients with systemic lupus erythematosus
F Flores-Borja et al.
ARTHRITIS AND RHEUMATISM (2005)
RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement
CM Lau et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus
A Cappione et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus
W Stohl et al.
ARTHRITIS AND RHEUMATISM (2005)
Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease
KA Kirou et al.
ARTHRITIS AND RHEUMATISM (2005)
Defective B cell tolerance checkpoints in systemic lupus erythematosus
S Yurasov et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Both innate immunity and type 1 humoral immunity to Streptococcus pneumoniae are mediated by MyD88 but differ in their relative levels of dependence on Toll-like receptor 2
AQ Khan et al.
INFECTION AND IMMUNITY (2005)
Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus
M Ramanujam et al.
JOURNAL OF IMMUNOLOGY (2004)
Type I IFN protects against murine lupus
JD Hron et al.
JOURNAL OF IMMUNOLOGY (2004)
Human blood IgM memory B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire
S Weller et al.
BLOOD (2004)
Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches
M Thien et al.
IMMUNITY (2004)
Predominant autoantibody production by early human B cell precursors
H Wardemann et al.
SCIENCE (2003)
Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6
G Jego et al.
IMMUNITY (2003)
Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen
S Kruetzmann et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice
ML Santiago-Raber et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Interferon and granulopoiesis signatures in systemic lupus erythematosus blood
L Bennett et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus
EC Baechler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis
DT Boumpas et al.
ARTHRITIS AND RHEUMATISM (2003)
B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus - Longitudinal observations
W Stohl et al.
ARTHRITIS AND RHEUMATISM (2003)
Anti-DNA B cells in MRL/lpr mice show altered differentiation and editing pattern
YJ Li et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Blood dendritic cells interact with splenic marginal zone B cells to initiate T-Independent immune responses
M Balázs et al.
IMMUNITY (2002)
DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL
MB Litinskiy et al.
NATURE IMMUNOLOGY (2002)
Balanced responsiveness to chemoattractants from adjacent zones determines B-cell position
K Reif et al.
NATURE (2002)
A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus
LA DeGiorgio et al.
NATURE MEDICINE (2001)
TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: Impaired B cell maturation in mice lacking BLyS
JA Gross et al.
IMMUNITY (2001)
Marginal zone and B1B cells unite in the early response against T-independent blood-borne particulate antigens
F Martin et al.
IMMUNITY (2001)
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease
JA Gross et al.
NATURE (2000)
Autoimmune-prone mice share a promoter haplotype associated with reduced expression and function of the Fc receptor FcγRII
NR Pritchard et al.
CURRENT BIOLOGY (2000)
分享论文
